Bliss GVS Pharma Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 6/6
Bliss GVS Pharma hat ein Gesamteigenkapital von ₹10.0B und eine Gesamtverschuldung von ₹878.1M, wodurch sich der Verschuldungsgrad auf 8.8% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen ₹12.1B bzw. ₹2.1B. Bliss GVS Pharma Das EBIT des Unternehmens beträgt ₹1.2B, so dass der Zinsdeckungsgrad 18 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von ₹2.2B.
Wichtige Informationen
8.8%
Verhältnis von Schulden zu Eigenkapital
₹878.07m
Verschuldung
| Zinsdeckungsgrad | 18x |
| Bargeld | ₹2.16b |
| Eigenkapital | ₹10.03b |
| Gesamtverbindlichkeiten | ₹2.11b |
| Gesamtvermögen | ₹12.14b |
Jüngste Berichte zur Finanzlage
Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?
Feb 20
Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?
Jul 14These 4 Measures Indicate That Bliss GVS Pharma (NSE:BLISSGVS) Is Using Debt Reasonably Well
May 21Bliss GVS Pharma (NSE:BLISSGVS) Has A Pretty Healthy Balance Sheet
Feb 08Is Bliss GVS Pharma (NSE:BLISSGVS) A Risky Investment?
Oct 25
Bliss GVS Pharma (NSE:BLISSGVS) Seems To Use Debt Quite Sensibly
Jul 21Recent updates
We Think Bliss GVS Pharma's (NSE:BLISSGVS) Solid Earnings Are Understated
May 10Bliss GVS Pharma Limited's (NSE:BLISSGVS) Price Is Right But Growth Is Lacking
Apr 27Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?
Feb 20There Is A Reason Bliss GVS Pharma Limited's (NSE:BLISSGVS) Price Is Undemanding
Jan 26Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?
Jul 14Bliss GVS Pharma (NSE:BLISSGVS) Has Affirmed Its Dividend Of ₹0.50
Sep 11Bliss GVS Pharma (NSE:BLISSGVS) Is Due To Pay A Dividend Of ₹0.50
Aug 28These 4 Measures Indicate That Bliss GVS Pharma (NSE:BLISSGVS) Is Using Debt Reasonably Well
May 21Estimating The Intrinsic Value Of Bliss GVS Pharma Limited (NSE:BLISSGVS)
Apr 08A Look At Bliss GVS Pharma's (NSE:BLISSGVS) Share Price Returns
Mar 18Here's How We Evaluate Bliss GVS Pharma Limited's (NSE:BLISSGVS) Dividend
Feb 25Bliss GVS Pharma (NSE:BLISSGVS) Has A Pretty Healthy Balance Sheet
Feb 08What Type Of Shareholders Make Up Bliss GVS Pharma Limited's (NSE:BLISSGVS) Share Registry?
Jan 21Do Its Financials Have Any Role To Play In Driving Bliss GVS Pharma Limited's (NSE:BLISSGVS) Stock Up Recently?
Jan 08How Is Bliss GVS Pharma's (NSE:BLISSGVS) CEO Paid Relative To Peers?
Dec 26Did Bliss GVS Pharma's (NSE:BLISSGVS) Share Price Deserve to Gain 14%?
Dec 13Should You Use Bliss GVS Pharma's (NSE:BLISSGVS) Statutory Earnings To Analyse It?
Nov 30Bliss GVS Pharma Limited (NSE:BLISSGVS) Insiders Increased Their Holdings
Nov 18Does Bliss GVS Pharma Limited (NSE:BLISSGVS) Have A Place In Your Dividend Portfolio?
Nov 06Is Bliss GVS Pharma (NSE:BLISSGVS) A Risky Investment?
Oct 25Is Bliss GVS Pharma Limited's (NSE:BLISSGVS) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Oct 07How Much Is Bliss GVS Pharma Limited (NSE:BLISSGVS) CEO Getting Paid?
Sep 19What Is The Ownership Structure Like For Bliss GVS Pharma Limited (NSE:BLISSGVS)?
Sep 04Have Insiders Been Buying Bliss GVS Pharma Limited (NSE:BLISSGVS) Shares?
Aug 17The Bliss GVS Pharma (NSE:BLISSGVS) Share Price Has Gained 43% And Shareholders Are Hoping For More
Aug 04Fewer Investors Than Expected Jumping On Bliss GVS Pharma Limited (NSE:BLISSGVS)
Aug 04Bliss GVS Pharma (NSE:BLISSGVS) Seems To Use Debt Quite Sensibly
Jul 21Should You Use Bliss GVS Pharma's (NSE:BLISSGVS) Statutory Earnings To Analyse It?
Jul 06Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: BLISSGVSDie kurzfristigen Aktiva des Unternehmens (₹8.1B) übersteigen seine kurzfristigen Passiva (₹1.6B).
Langfristige Verbindlichkeiten: BLISSGVSDie kurzfristigen Vermögenswerte des Unternehmens (₹8.1B) übersteigen seine langfristigen Verbindlichkeiten (₹510.6M).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: BLISSGVS über mehr Barmittel verfügt als seine Gesamtverschuldung.
Schulden abbauen: BLISSGVS Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 15.4% auf 8.8% zurückgegangen.
Schuldendeckung: BLISSGVSDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (173.6%).
Zinsdeckung: BLISSGVSDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (18x Coverage) gut gedeckt.